Efficacy and safety of fish oil supplementation combined with low-dose isotretinoin for moderate-to-severe acne vulgaris: A randomized controlled non-inferiority trial
Sungkhasunya P, Asawanonda P, Kumtornrut C
Journal of the American Academy of Dermatology · 1 cita
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- King Chulalongkorn Memorial Hospital
- Universidad u hospital
- Faculty of Medicine, Chulalongkorn University
- Subvenciones
- Faculty of Medicine, Chulalongkorn University (RA68/005)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-03-05 · J Am Acad Dermatol · vol. 95 · número 2 · págs. 416–422
- Editorial
- Elsevier BV
- Citado
- 1 cita · más que el 92% de estudios similares · 6.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 14 trabajos
- Acceso
- De pago
- Áreas de investigación
- Acne and Rosacea Treatments and Effects · Dermatology and Skin Diseases · Dermatologic Treatments and Research
- Palabras clave
- fish oil supplementation, isotretinoin, acne, low-dose isotretinoin, non-inferiority, combination therapy, serum triglycerides, skin hydration, mucocutaneous adverse effects, liver transaminases, young adults
- MeSH
- humans, acne vulgaris, isotretinoin, fish oils, dermatologic agents, treatment outcome, drug therapy, combination, severity of illness index, double-blind method, dose-response relationship, drug, dietary supplements, adolescent, adult, female, male, young adult
3 autores
- Parnpetch Sungkhasunya🇹🇭Chulalongkorn University
- Pravit Asawanonda🇹🇭Chulalongkorn University
- Chanat Kumtornrut🇹🇭 · autor de correspondenciaThai Red Cross Society; Chulalongkorn University; King Chulalongkorn Memorial Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Isotretinoin is a treatment for moderate-to-severe acne, but it is limited by side effects. Fish oil may reduce these side effects; however, its impact on the clinical efficacy and safety of low-dose isotretinoin in the treatment of acne vulgaris has not been evaluated.
Objective
To compare the efficacy and safety of low-dose isotretinoin combined with fish oil versus low-dose isotretinoin monotherapy in moderate-to-severe acne.
Methods
In this randomized, double-masked, controlled, non-inferiority trial, participants aged 18 to 25 years with an acne Investigator's Global Assessment (IGA) score ≥3 received 10-mg isotretinoin with 1-g fish oil (n = 40) or placebo (n = 40) once daily for 3 months. Outcomes included acne counts, IGA scores, skin biophysics, mucocutaneous adverse effects, serum triglyceride (TG), and liver transaminases.
Results
The fish oil group was noninferior to the placebo group in reducing total acne counts from baseline (between-group mean difference: -6.0; 95% CI: -16.5 to 4.5). Fish oil also showed smaller reductions in corneometer values and smaller increases in TG levels.
Limitations
The use of IGA-based inclusion criteria may have influenced the non-inferiority analysis and the 3-month duration may limit long-term interpretation.
Conclusion
Fish oil combined with low-dose isotretinoin is noninferior and may preserve skin hydration and TG control.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.